Expertise in
12
conditions

Dr. Nizar M. Tannir

Oncology | Urology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Expertise in
12
conditions
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nizar Tannir is an Oncologist and an Urologist in Houston, Texas. Dr. Tannir is highly rated in 12 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Neuroendocrine Tumor, Nephrectomy, and Orchiectomy.

His clinical research consists of co-authoring 292 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Urology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Hawaii Medical Assurance Association
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Everolimus, Lenvatinib
Study Phase: Phase 2
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine, Gemcitabine Hydrochloride, Ixazomib, Ixazomib Citrate
Study Phase: Phase 2
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: DFF332, RAD001, PDR001, NIR178
Study Phase: Phase 1
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Nivolumab, Sitravatinib
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 6 Less Clinical Trials

292 Total Publications

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Journal: Urologic oncology
Published: May 12, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Seth P. Lerner
Urology | Oncology
Expertise in
12
conditions
Dr. Seth P. Lerner
Urology | Oncology

Baylor College Of Medicine

6770 Bertner Ave, Suite C 350, 
Houston, TX 
 (0.5 miles away)
713-798-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Seth Lerner is an Urologist and an Oncologist in Houston, Texas. Dr. Lerner is highly rated in 12 conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Hagop M. Kantarjian
Expertise in
47
conditions
Dr. Hagop M. Kantarjian
Oncology | Hematology
Expertise in
47
conditions
Dr. Hagop M. Kantarjian
Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist and a Hematologist in Houston, Texas. Dr. Kantarjian is highly rated in 47 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
35
conditions
Dr. Naveen M. Pemmaraju
Oncology | Hematology
Expertise in
35
conditions
Dr. Naveen M. Pemmaraju
Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naveen Pemmaraju is an Oncologist and a Hematologist in Houston, Texas. Dr. Pemmaraju is highly rated in 35 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tannir's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile